Provided by Tiger Trade Technology Pte. Ltd.

MADER GROUP LTD

8.260
-0.240-2.82%
Volume:6.98K
Turnover:57.41K
Market Cap:1.68B
PE:30.55
High:8.490
Open:8.490
Low:8.150
Close:8.500
52wk High:9.630
52wk Low:5.044
Shares:203.46M
Float Shares:55.68M
Volume Ratio:0.39
T/O Rate:0.01%
Dividend:0.09
Dividend Rate:1.07%
EPS(TTM):0.270
EPS(LYR):0.270
ROE:30.67%
ROA:14.60%
PB:7.92
PE(LYR):30.55

Loading ...

BRIEF-Mader Posts H1 Net Income AUD 30.5 Million

Reuters
·
Yesterday

Mader Group Posts Higher Fiscal H1 Earnings, Revenue; Reaffirms Fiscal 2026 Outlook

MT Newswires Live
·
Yesterday

Mader H1 Ebitda AUD 56.2 Million

THOMSON REUTERS
·
Yesterday

Mader Group Ltd - Outlook for All Segments for 2H FY26 and FY27 Is Increasingly Positive

THOMSON REUTERS
·
Yesterday

Mader H1 Revenue AUD 485.2 Million

THOMSON REUTERS
·
Yesterday

Insiders At Mader Group Sold AU$44m In Stock, Alluding To Potential Weakness

Simply Wall St.
·
Feb 07

Why Mader Group (ASX:MAD) Is Up 11.3% After Broker Upgrade And New 5-Year Strategy Unveiling

Simply Wall St.
·
Jan 23

A Look At Mader Group’s Valuation As Quarterly Results And Broker Upgrade Lift Attention

Simply Wall St.
·
Jan 19

Bell Potter Upgrades Mader Group to Buy from Hold, Price Target is AU$9

MT Newswires Live
·
Jan 16

With EPS Growth And More, Mader Group (ASX:MAD) Makes An Interesting Case

Simply Wall St.
·
Dec 26, 2025

Despite selling recently, Mader Group Limited (ASX:MAD) insiders own 68% stake and recent decline might have cost them

Simply Wall St.
·
Dec 10, 2025

Mader Group's (ASX:MAD) five-year total shareholder returns outpace the underlying earnings growth

Simply Wall St.
·
Nov 18, 2025

Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025

prnewswire
·
Nov 05, 2025

Mader Group Limited's (ASX:MAD) Popularity With Investors Is Under Threat From Overpricing

Simply Wall St.
·
Nov 04, 2025

Mader Group Targets Revenue of at Least AU$1 Billion in Fiscal 2026

MT Newswires Live
·
Oct 31, 2025

Is Mader Group (ASX:MAD) Using Too Much Debt?

Simply Wall St.
·
Oct 22, 2025

PYC Therapeutics Advances to Multiple-Dose Study of Drug Candidate in Patients with Blinding Eye Disease; Shares Down 4%

MT Newswires Live
·
Oct 09, 2025

Why You Should Care About Mader Group's (ASX:MAD) Strong Returns On Capital

Simply Wall St.
·
Oct 02, 2025

Don't Ignore The Insider Selling In Mader Group

Simply Wall St.
·
Sep 14, 2025